Physician profile
Mark Daniel Dollard
NPI 1427049766
$1,618.22
in general payments reported to CMS, 2019-2025
19 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2021: $122 · 2022: $395 · 2023: $228 · 2024: $305 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Entertainment: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.82 |
| Entertainment | $132.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $234.91 | 2019-2024 | Kimyrsa |
| Medtronic, INC. | $166.65 | 2023-2024 | Intellis Adaptivestim |
| Bone Support INC. | $132.67 | 2021-2022 | |
| Nuo Therapeutics | $132.15 | 2025 | |
| Convatec INC. | $124.99 | 2024 | |
| Bioventus LLC | $124.99 | 2022 | |
| Triad Life Sciences INC. | $112.04 | 2022 | |
| Abbott Laboratories | $102.94 | 2023 | Diamondback Peripheral |
| Embody, INC. | $88.55 | 2022 | |
| Osiris Therapeutics INC. | $80.79 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $78.11 | 2019 | |
| Zimmer Biomet Holdings, INC. | $77.07 | 2019 | |
| Smith+Nephew, INC. | $36.33 | 2021-2022 | |
| Averitas Pharma INC. | $28.79 | 2024 | Qutenza |
| Terumo Medical Corporation | $23.11 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novastep INC. | $22.05 | 2025 | Nexis |
| Urgo Medical North America, LLC | $21.46 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Fidia Pharma USA INC. | $19.56 | 2019 | |
| Integra Lifesciences Corporation | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.